TG Therapeutics, Inc.
TGTX
$37.25
-$0.10-0.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 329.00M | 264.79M | 346.73M | 289.33M | 233.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 329.00M | 264.79M | 346.73M | 289.33M | 233.66M |
| Cost of Revenue | 38.49M | 30.94M | 25.11M | 18.72M | 14.13M |
| Gross Profit | 290.52M | 233.85M | 321.62M | 270.62M | 219.53M |
| SG&A Expenses | 154.30M | 146.49M | 137.29M | 129.22M | 122.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 287.08M | 265.30M | 244.88M | 240.98M | 213.03M |
| Operating Income | 41.93M | -505.00K | 101.85M | 48.36M | 20.63M |
| Income Before Tax | 25.59M | -13.89M | 95.78M | 41.62M | 13.06M |
| Income Tax Expenses | 2.21M | 479.00K | 91.00K | 419.00K | 390.00K |
| Earnings from Continuing Operations | 23.38 | -14.36 | 95.69 | 41.20 | 12.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.38M | -14.36M | 95.69M | 41.20M | 12.67M |
| EBIT | 41.93M | -505.00K | 101.85M | 48.36M | 20.63M |
| EBITDA | 42.00M | -408.00K | 102.00M | 48.53M | 20.84M |
| EPS Basic | 0.16 | -0.10 | 0.67 | 0.29 | 0.08 |
| Normalized Basic EPS | 0.11 | -0.06 | 0.42 | 0.18 | 0.05 |
| EPS Diluted | 0.14 | -0.11 | 0.60 | 0.22 | 0.01 |
| Normalized Diluted EPS | 0.10 | -0.06 | 0.38 | 0.14 | 0.01 |
| Average Basic Shares Outstanding | 581.28M | 579.13M | 576.90M | 573.68M | 567.78M |
| Average Diluted Shares Outstanding | 626.59M | 609.44M | 604.60M | 586.68M | 580.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
